Endometrial Cancer Trial, Recruiting NCT04845828 Sponsor: Asan Medical Center Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04845828
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women between 20 and 80 years old
  • People who have been diagnosed with uterine (endometrial) cancer confirmed by a tissue sample, and have not yet received any treatment for it
  • People whose cancer is one of several specific types, including endometrioid, mucinous, serous, clear cell, undifferentiated, dedifferentiated, mesonephric adenocarcinoma, mesonephric-like adenocarcinoma, carcinosarcoma, or mixed type
  • People whose cancer falls within certain grading categories (FIGO grade 1, 2, or 3)
  • People whose cancer is thought to be at an early stage (presumed FIGO stage I or II)
  • People who are planned to have a keyhole (laparoscopic) or robotic surgery to remove the uterus and nearby lymph nodes
  • People whose largest pelvic or abdominal lymph node measures 15 mm or less on the short side, as seen on an MRI scan
  • People who are in reasonably good general health, able to carry out daily activities with little or no difficulty (ECOG performance status 0–2)
  • People rated as low surgical risk by their anaesthetist (ASA physical status 0–2)
  • People whose blood test results meet the required levels for white blood cells, platelets, kidney function, and liver function (confirm with trial site for specific values)
  • People who have voluntarily agreed to take part and signed a consent form

Who may not be able to join:

  • People whose cancer is thought to have spread more widely (presumed FIGO stage III or IV)
  • People whose cancer is of a neuroendocrine tumour type
  • People who have another disease affecting their lymphatic system
  • People who already have lymphoedema (swelling caused by fluid build-up) in the lower legs, groin, or surrounding area
  • People who have previously had surgery to remove pelvic or abdominal lymph nodes
  • People who have previously had radiotherapy or combined chemotherapy and radiotherapy to the abdomen or pelvis
  • People who have previously received chemotherapy for a cancer in the abdomen or pelvis
  • People who have had or been treated for another cancer within the past five years, with the exception of certain skin cancers or early-stage cervical, stomach, or bladder lesions (confirm specific exceptions with trial site)
  • People with serious or poorly controlled ongoing health conditions, or existing conditions that have led to complications
  • People with a known allergy to indocyanine green (a dye used during surgery)
  • People who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +82-2-3010-3646

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
26 January 2022
Est. completion
1 December 2027

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

The 3-year disease-free survival (3-year DFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov